1-烯丙氧基丁烷2-甲基噁丙环并噁丙环 | 107016-79-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 1-烯丙氧基丁烷2-甲基噁丙环并噁丙环
• 中文别名: 8,8'-二硫代二-辛酸
• 英文名称: Octanoic acid,8,8'-dithiobis-
• 英文别名: 8-(7-carboxyheptyldisulfanyl)octanoic acid
• CAS: 107016-79-5
• 化学式: C₁₆H₃₀O₄S₂
• 分子量: 350.5
• InChiKey: VMTVUDJOOMHKPO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  22
• 可旋转键数：
  17
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  125
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• PRODUCTION OF POLYMER HYDROXYLATED AT BOTH TERMINALS, COMPOSITION CONTAINING SAID POLYMER AND ITS USE, AND POLYMER DERIVED FROM SAID COMPOSITION AND ITS USE
  申请人：NIPPON SHOKUBAI CO., LTD.

  公开号：EP0552376A1

  公开（公告）日：1993-07-28

  A process for efficiently producing a polymer hydroxylated at both terminals from a variety of vinyl monomers readily at a low cost, which comprises polymerizing a vinyl monomer (b) by using a radical polymerization initiator (c) in the presence of a compound (a) represented by the general formula HO-A-(S)x-B-OH in such a manner that the reaction system is substantially free from any reactants other than the components (a), (b) and (c), and the amount of the component (a) present in the reaction vessel is at least 50 times by mole as large as that of the component (c) throughout the reaction.

  一种利用各种乙烯基单体以低成本高效生产两端羟基化的聚合物的工艺，该工艺包括在通式 HO-A-(S)x-B-OH 所代表的化合物(a)存在下，通过使用自由基聚合引发剂(c)使乙烯基单体(b)聚合，反应体系中除组分(a)、(b)和(c)外基本上不含任何反应物，并且在整个反应过程中，反应容器中组分(a)的存在量至少是组分(c)的 50 倍（摩尔）、(b)和(c)以外的任何反应物，并且在整个反应过程中，反应容器中存在的组分(a)的量至少是组分(c)的 50 倍（按摩尔计）。
• COATED MAGNETIC PARTICLE CONTAINING PREPARATION, PROCESS FOR PRODUCING THE SAME AND DIAGNOSTIC THERAPEUTIC SYSTEM
  申请人：Konica Minolta Medical & Graphic, Inc.

  公开号：EP1842554A1

  公开（公告）日：2007-10-10

  It is an object of the invention to provide a pharmaceutical preparation containing magnetic vesicular particles which enables selective delivery of agents to a tumor site (targeting capability), is applicable to a contrast medium material or drug transport carrier and is also usable in thermotherapy employing heat-generation, and diagnosis and treatment of cancer by combinations thereof, and further a manufacturing method thereof and a diagnostic therapeutic system by use thereof. There is disclosed a pharmaceutical preparation comprising magnetic vesicular particles, wherein the magnetic vesicular particles each include one or more magnetic microparticles within a lipid membrane, the magnetic microparticle having particulate gold attached to the surface of the magnetic microparticles and further having an organic compound bound to the particulate gold; and the vesicular particles meet the following requirement: wherein R is an average particle size of the magnetic vesicular particles and r is an average particle size of the magnetic microparticles included in the magnetic vesicular particles.

  本发明的目的是提供一种含有磁性囊状微粒的药物制剂，该药物制剂可选择性地将药剂输送到肿瘤部位（靶向能力），适用于造影剂材料或药物运输载体，也可用于热疗（利用发热），以及通过其组合诊断和治疗癌症，并进一步提供其制造方法和利用其制造的诊断治疗系统。 本发明公开了一种药物制剂，该药物制剂包括磁性囊状颗粒，其中磁性囊状颗粒包括脂膜中的一个或多个磁性微粒，磁性微粒表面附着有微粒金，微粒金上还结合有有机化合物；囊状颗粒符合以下要求： 其中 R 是磁性囊状颗粒的平均粒径，r 是磁性囊状颗粒中包含的磁性微粒的平均粒径。
• Reduction catalyst and chemical reactor
  申请人：KABUSHIKI KAISHA TOSHIBA

  公开号：US10308574B2

  公开（公告）日：2019-06-04

  According to one embodiment, a reduction catalyst includes a current collector including a metal layer; and organic molecules including a quaternary nitrogen cation, which are bonded to the metal layer. The organic molecules are represented by any of the following general formulae I to V.

  根据一个实施方案，还原催化剂包括一个集流器，其中包括金属层；以及有机分子，其中包括与金属层结合的季氮阳离子。有机分子由以下通式 I 至 V 中的任一通式表示。
• Pharmaceutical preparation containing magnetic vesicular particles, manufacturing method thereof and diagnostic therapeutic system
  申请人：Takeyama Toshihisa

  公开号：US20060171894A1

  公开（公告）日：2006-08-03

  A pharmaceutical preparation comprising magnetic vesicular particles, wherein the magnetic vesicular particles each include one or more magnetic microparticles within a lipid membrane, the magnetic microparticle having particulate gold attached to the surface of the magnetic microparticles and further having an organic compound bound to the particulate gold; and the vesicular particles meet the following requirement: 0.02≦ R /( r ×100)≦0.03 wherein R is an average particle size of the magnetic vesicular particles and r is an average particle size of the magnetic microparticles included in the magnetic vesicular particles.

  一种药物制剂，包括磁性囊状颗粒，其中磁性囊状颗粒包括一个或多个位于脂膜内的磁性微粒，磁性微粒表面附着有微粒金，微粒金上还结合有有机化合物；囊状颗粒满足以下要求： 0.02≦ R /( r ×100)≦0.03 其中 R 是磁性囊状颗粒的平均粒径，r 是磁性囊状颗粒中包含的磁性微颗粒的平均粒径。
• POLYURETHANE
  申请人：Compagnie Générale des Etablissements Michelin

  公开号：EP2115033B1

  公开（公告）日：2017-05-17